Geode Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $47.6M | Sell |
|
|||||
|
2025
Q2 | $62.3M | Buy |
|
|||||
|
2025
Q1 | $59.6M | Buy |
|
|||||
|
2024
Q4 | $65.8M | Sell |
|
|||||
|
2024
Q3 | $87.3M | Buy |
|
|||||
|
2024
Q2 | $61.9M | Buy |
|
|||||
|
2024
Q1 | $62.6M | Buy |
|
|||||
|
2023
Q4 | $61.4M | Buy |
|
|||||
|
2023
Q3 | $38.6M | Buy |
|
|||||
|
2023
Q2 | $48.9M | Buy |
|
|||||
|
2023
Q1 | $40.7M | Buy |
|
|||||
|
2022
Q4 | $45.5M | Buy |
|
|||||
|
2022
Q3 | $38.3M | Buy |
|
|||||
|
2022
Q2 | $54.2M | Buy |
|
|||||
|
2022
Q1 | $65.6M | Buy |
|
|||||
|
2021
Q4 | $73.7M | Buy |
|
|||||
|
2021
Q3 | $76.3M | Buy |
|
|||||
|
2021
Q2 | $77.7M | Sell |
|
|||||
|
2021
Q1 | $123M | Buy |
|
|||||
|
2020
Q4 | $135M | Buy |
|
|||||
|
2020
Q3 | $70.6M | Buy |
|
|||||
|
2020
Q2 | $67.1M | Buy |
|
|||||
|
2020
Q1 | $36.3M | Buy |
|
|||||
|
2019
Q4 | $31.8M | Buy |
|
|||||
|
2019
Q3 | $31.3M | Buy |
|
|||||
|
2019
Q2 | $46M | Buy |
|
|||||
|
2019
Q1 | $46.6M | Buy |
|
|||||
|
2018
Q4 | $24.7M | Buy |
|
|||||
|
2018
Q3 | $38.6M | Buy |
|
|||||
|
2018
Q2 | $36.9M | Buy |
|
|||||
|
2018
Q1 | $22.2M | Buy |
|
|||||
|
2017
Q4 | $16.8M | Sell |
|
|||||
|
2017
Q3 | $19.4M | Buy |
|
|||||
|
2017
Q2 | $21.6M | Buy |
|
|||||
|
2017
Q1 | $22.6M | Buy |
|
|||||
|
2016
Q4 | $21M | Buy |
|
|||||
|
2016
Q3 | $19.5M | Buy |
|
|||||
|
2016
Q2 | $12.9M | Buy |
|
|||||
|
2016
Q1 | $16.3K | Buy |
|
|||||
|
2015
Q4 | $27.8M | Buy |
|
|||||
|
2015
Q3 | $22.9M | Buy |
|
|||||
|
2015
Q2 | $19.4M | Buy |
|
|||||
|
2015
Q1 | $8.68M | Buy |
|
|||||
|
2014
Q4 | $5.39M | Sell |
|
|||||
|
2014
Q3 | $7.08M | Buy |
|
|||||
|
2014
Q2 | $1.65M | Buy |
|
|||||
|
2014
Q1 | $1.76M | Buy |
|